Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

pies in the class of oncolytic immunotherapies," stated David H. Kirn, M.D., founder, chief medical officer and president of R&D of Jennerex.  "In the Phase 2 trial presented at ILCA, JX-594 demonstrated its ability to selectively target and destroy tumors following intravenous infusion. This finding confirms the ability of JX-594 to target both primary and metastatic, or distant, tumors which we believe is important in this HCC patient population and most cancers."

"We have treated more than 160 patients with JX-594 to date and are actively enrolling a multinational Phase 2b study in second line treatment of liver cancer patients, a Phase 2 all-IV trial in first line HCC patients, and a Phase 2 study in colorectal cancer.  The data presented today build on the growing body of promising clinical data showing that JX-594 has a direct anti-tumor effect and can stimulate an immune response killing cancer cells," stated Laurent Fischer, M.D., president and chief executive officer of Jennerex. "We are excited with the progress we are making in our JX-594 program and believe it has the potential to advance patient care across multiple types of cancer."

The abstract (#2012-1304) entitled "Phase 2 Trial Of JX-594, A Targeted Multi-Mechanistic Oncolytic Vaccinia Virus, Followed By Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)" was presented at the International Liver Cancer Association Annual Meeting in Berlin.

About this Trial:

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intratumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

Following treatment with JX-594 alone at four weeks, 62 percent of patients had disease control as measured by modified RECIST (tumor burden measurement). 
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Research ... "Global Respiratory Devices Market 2014-2018" report to ... A respiratory device is a medical device ... is having difficulty in breathing and cannot achieve adequate ... such as cystic fibrosis, asthma, COPD, and ARDS require ...
(Date:7/29/2014)... Ill. , July 29, 2014  Sysmex America, ... and information systems technology, will feature an exhibit booth ... Annual Meeting and Clinical Lab Expo in ... 2014. "We are extremely excited to ... opportunity to interact with our customers and continue the ...
(Date:7/29/2014)... Calif. , July 29, 2014  Based ... response systems (PERS) market, Frost & Sullivan recognizes ... Sullivan Award for Price Performance Value Leadership. MobileHelp,s ... directly captures expectations for tech progression in personal ... consumers for these solutions. MobileHelp is ...
Breaking Medicine Technology:Global Respiratory Devices Market 2014-2018 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... America, Inc. (SAI), a leading medical diagnostic instrument ... Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ... for Sysmex America, Inc. to provide fully automated ... of the systems has been completed.   ...
... Medical Systems (NYSE: VAR ) will hold an ... of  the American Society for Therapeutic Radiology and Oncology (ASTRO) ... are invited to join senior management for a review of ... at ASTRO. Varian will host a meeting with ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent ... Chiropractic Association (FCA) National Convention and Expo, speaking on ... Chain Changes on Thursday, August 20th at the Hyatt ... the positive impact functional foot orthotics, like Foot Levelers ... pain, plantar fasciitis, and hammertoes. , Invented by a ...
(Date:7/29/2014)... Healthcare staffing agency Medical Solutions ... Tomorrow Scholarship Competition winners:, ,     Alonso ...     Racheal D., Freshman, Cerritos College in Norwalk, ... College in Houston, TX , Each ... hosts the Nurses of Tomorrow Scholarship competition as ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen ... will utilize the Global Data Synchronization Network™ (GDSN®) ... share product information with the U.S. Food and ... their global supply chain. Holger Clobes, Head of ... "B. Braun serves customers in 61 countries, among ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... recommendations for the diagnosis and subsequent treatment of superior ... the New England Journal of Medicine. ,The ... vena cava syndrome, provides clinical management evidence, and presents ... Lynn D. Wilson, M.D., MPH, Professor, Clinical Director, and ...
... need medical care in Korea but can afford it ... health services, according to a Yale School of ... Health. ,Low-income individuals with multiple chronic ... restrictions because they need and use more services, said ...
... to create therapies or simply investigate how organisms develop, ... of biological science's toughest assignments: keeping their tiny research ... notoriously finicky tastes, and despite a decade of advances, ... cells will continue dividing indefinitely in culture or begin ...
... needed to determine the true effects of low to ... impact on pregnant women of different policies on ... ,Recommendations for safe levels of drinking during ... organisations in Australia, according to new report written by ...
... of yoghurt could contain the cure for certain types ... . ,Overuse of antibiotics has led ... vancomycin-resistant enterococci (VRE), which are responsible for persistent and ... commercial yoghurts, may have a beneficial effect on human ...
... deceased older donors on a pump as opposed to ... cooler may lower hospital costs, improve initial organ ... according to new research by Wake Forest University Baptist Medical ... preservation times can be safely extended to permit more time ...
Cached Medicine News:Health News:Clinical Approach Defined for Superior Vena Cava Syndrome 2Health News:Poor and Chronically Ill in Korea Pay More for Healthcare 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Better Research Needed On Alcohol In Pregnancy 2Health News:Preserving Kidneys on a Pump May Promote More Organ Sharing 2
100L...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: